Glioblastoma is a major cause of cancer related death in the United States, with approximately 17,000 new cases of brain cancer diagnosed annually. Unfortunately, therapy remains inadequate and the mortality rate is high. Limited success in the treatment of glioblastoma has been demonstrated with the alkylating agent Temozolomide (TMZ). However, as with many alkylating agents, drug resistance has limited its efficacy. The base excision repair (BER) pathway provides significant resistance to TMZ by repairing greater than 80% of the TMZ-induced base lesions. As such, it is reasonable to expect that BER provides a significant level of resistance to TMZ and therefore enhanced TMZ efficacy may be obtained by blocking or interrupting repair and thereby promoting BER failure. The overall goals of this project are to utilize strategies to circumvent resistance to TMZ to enhance the cytotoxicity and potentially the efficacy of this alkylating agent. As the rate-limiting enzyme in BER, DNA polymerase ss (Polss) is important to facilitate repair and to maintain cell survival following DNA damage. Therefore, inhibition of Polss will enhance TMZ response. Specifically, we wil characterize a novel regulatory mechanism of Polss (lysine di-methylation) that can be exploited to inhibit Polss and enhance alkylating agent-induced cell death by enhancing the accumulation of cytotoxic BER intermediates (Aim 1). We posit that Polss inhibition or BER failure signals via poly(ADP)ribose (PAR) synthesis and NAD+/ATP depletion by a process that requires activation of PARP1 &PARP2 and is regulated by the enzyme PARG. We find that BER failure- induced cell death results from energy (NAD+ &ATP) depletion due to elevated PAR synthesis mediated by the PARP1/PARP2 BER sensor complex, suggesting that the response to TMZ can be enhanced via increased PAR synthesis or depletion of cellular NAD+ synthesis (Aim 2) and/or deregulation of the BER enzyme PARG (Aim 3). Overall, we will test the hypothesis that the BER pathway is a determinant of resistance to TMZ and therefore selectively targeting the BER pathway will significantly enhance TMZ efficacy. In each of our three specific aims, our goals are to identify and functionally characterize key elements of the BER pathway that control cellular responses to alkylating agents with the goal of increasing TMZ-induced cytotoxicity in cells from glioma tumors. Relevance: The proposed studies will provide new biomarkers of response to alkylation-induced DNA damage and cell death and provide insight into mechanisms that can be exploited to enhance response. Insights gained from these studies have the potential to identify novel targets for adjuvant therapies including BER inhibitors and NAD+ biosynthesis modulators that can be combined with alkylators to improve anticancer drug efficacy.
Glioblastoma is a major cause of cancer related death in the United States, with approximately 17,000 new cases of brain cancer diagnosed annually. Unfortunately, therapy remains inadequate and the mortality rate is high. Limited success in the treatment of glioblastoma has been demonstrated with the alkylating agent temozolomide (TMZ). However, as with many alkylating agents, drug resistance from active DNA repair pathways limits its efficacy. Overall, we will test the hypothesis that the base excision repair (BER) pathway is a determinant of resistance to TMZ and therefore selectively targeting critical BER pathway proteins will significantly enhance TMZ efficacy. The proposed studies will provide new biomarkers of response to temozolomide-induced DNA damage and cell death and provide insight into mechanisms that can be exploited to enhance response and to identify novel targets for adjuvant therapies.
|Wang, Jingnan; Li, Jianfeng; Santana-Santos, Lucas et al. (2015) A novel strategy for targeted killing of tumor cells: Induction of multipolar acentrosomal mitotic spindles with a quinazolinone derivative mdivi-1. Mol Oncol 9:488-502|
|Fang, Qingming; Inanc, Burcu; Schamus, Sandy et al. (2014) HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase ?. Nat Commun 5:5513|
|Bennett, Geoffrey R; Peters, Ryan; Wang, Xiao-hong et al. (2014) Repair of oxidative DNA base damage in the host genome influences the HIV integration site sequence preference. PLoS One 9:e103164|
|Choi, Yong Jun; Li, Han; Son, Mi Young et al. (2014) Deletion of individual Ku subunits in mice causes an NHEJ-independent phenotype potentially by altering apurinic/apyrimidinic site repair. PLoS One 9:e86358|
|Fouquerel, Elise; Sobol, Robert W (2014) ARTD1 (PARP1) activation and NAD(+) in DNA repair and cell death. DNA Repair (Amst) 23:27-32|
|Agnihotri, Sameer; Burrell, Kelly; Buczkowicz, Pawel et al. (2014) ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov 4:1198-213|
|Fouquerel, Elise; Goellner, Eva M; Yu, Zhongxun et al. (2014) ARTD1/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD+ depletion. Cell Rep 8:1819-31|
|Lan, Li; Nakajima, Satoshi; Wei, Leizhen et al. (2014) Novel method for site-specific induction of oxidative DNA damage reveals differences in recruitment of repair proteins to heterochromatin and euchromatin. Nucleic Acids Res 42:2330-45|
|Kothandapani, Anbarasi; Sawant, Akshada; Dangeti, Venkata Srinivas Mohan Nimai et al. (2013) Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Res 41:7332-43|
|Joshi, Kaushal; Banasavadi-Siddegowda, Yeshavanth; Mo, Xiaokui et al. (2013) MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 31:1051-63|
Showing the most recent 10 out of 25 publications